Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...
Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering. In its latest SEC filing, the company said it was planning to offer 7.5M ...
MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, has a portfolio of products aimed at ...
PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a $77.5 million market cap company known for its focus on non-opioid pain management products, reported that the U.S. Food and Drug ...
DALLAS - Spectral AI, Inc. (NASDAQ:MDAI), a Dallas-based company specializing in medical diagnostics with its AI-driven DeepView® System, has announced its expected financial outcomes for the year ...
LONDON and NEW YORK - OKYO Pharma Limited (NASDAQ: OKYO), a $36.54 million market cap biotechnology company currently trading at $1.04 per share, engaged in the development of treatments for ocular ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
EcoR1's involvement with Zymeworks extends beyond stock ownership, as Scott Platshon, an employee of EcoR1, serves as a ...
Many products sold by companies aren't must-have items. However, healthcare is a necessity. And the healthcare sector is poised to grow over the next decade and beyond with aging populations around ...
Stifel analysts began coverage of Edgewise Therapeutics (NASDAQ:EWTX), currently valued at $2.6 billion, with a Hold rating and set a price target of $30.00. According to InvestingPro data, the stock ...